News

London leads this increasingly important study by a huge margin, finds new study

Total revenues were $5.6 billion in 2018 compared to $6.5 billion in 2017

The drug was one of the company’s few original experimental drugs close to reaching the market

The new PharmaTimes Medical and Scientific Excellence Awards, designed to recognise the outstanding achievements of medical and scientific professionals will close for entry on the 31^st October.

Company announces revised agreement with Galapagos

Ruling secure Biogen’s Tecfidera exclusiity until 2028.

Drug significantly extended metastasis-free survival compared to placebo

CRO hopes partnership will accelerate drugs’ time to market

Company says drug could ‘play an important role in delaying the progression of smoldering myeloma into active myeloma’

Roche Diagnostics tests among seven selected for new scheme

Includes data for head and neck cancer, biliary tract cancer and esophageal cancers

MSD’s immunotherapy improved overall survival by up to 39%

Drug improved progression-free survival by 70%

Positive results in lung and breast cancer, but Roche is still playing catch-up to rival drugs

AMI-MS delivers a twenty-fold improvement in throughput compared to traditional mass spectrometry by using sound energy